Latest Non-Hodgkin lymphoma Stories
Overall Response Rate of 66 Percent Observed in Pembrolizumab-treated Patients Whose Cancer Progressed on Brentuximab Vedotin Phase 2 Study Planned for the First Half of 2015
Comprehensive market research report “Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment
PRINCETON, N.J., Nov. 17, 2014 /PRNewswire/ -- Soligenix, Inc.
DALLAS, October 29, 2014 /PRNewswire/ -- ReportsnReports.com adds Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising Pipeline
New research report “Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting” elaborated by GBI Research
- Total Deal Valued at up to Approximately $133.5 Million; Approximately $18.1 million Upfront - SEATTLE, Sept. 17, 2014 /PRNewswire/ -- CTI BioPharma Corp.
MarketOptimizer.org adds “OpportunityAnalyzer: Non-Hodgkin’s B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018” to its store.
Lack of Access and Financial Burden May Contribute to Increased Mortality, CPIC Researchers Find Fremont, CA (PRWEB) August 19, 2014 Despite advances
Participants to Produce Strategic Roadmap for Accelerating Lymphoma Treatment Advances WASHINGTON, Aug.
- A transitional zone between two communities containing the characteristic species of each.